Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.616595 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.616595 33613542!7892464!33613542     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 616595 Nephropedia Template TP {{tp|p=33613542|t=2020. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects |pdf=|usr=}}{{33613542}} gab.com Text Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33613542 #FOAvip By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed cases and 1.6 million related deaths around the world. However, only a few drugs have been approved in certain areas and for use in conditional patients, and the vaccine candidates were only recently approved or authorized for emergency use without being fully implemented worldwide, suggesting that we are yet to reach effective control of the current outbreak as its uninhibited transmission continues precariously. Over the past few months, several therapeutic candidates have been proven ineffective in large clinical trials, while some other agents exhibited promising preliminary results. Meanwhile, the investigation of SARS-CoV-2-specific antivirals is underway. Despite still being preclinical, these agents could be beneficial for the long-term control of COVID-19 and deserve more research focus. In this article, we update the current status of therapeutic candidates that have been examined for COVID-19 management, including the virus-targeting inhibitors and host-targeting agents, with their antiviral efficacy in vitro, in vivo, and in clinical studies. Finally, we highlight the current challenges and future prospect of developing potent therapeutic agents against COVID-19. Twit Text FOAVip Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33613542 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33613542 #FOAvip English Wikipedia <ref>{{Cite pmid|33613542}}</ref> Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects #MMPMID33613542 Liu CH; Lu CH; Wong SH; Lin LT Front Immunol 2020[]; 11 (ä): 616595 PMID33613542show ga By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed cases and 1.6 million related deaths around the world. However, only a few drugs have been approved in certain areas and for use in conditional patients, and the vaccine candidates were only recently approved or authorized for emergency use without being fully implemented worldwide, suggesting that we are yet to reach effective control of the current outbreak as its uninhibited transmission continues precariously. Over the past few months, several therapeutic candidates have been proven ineffective in large clinical trials, while some other agents exhibited promising preliminary results. Meanwhile, the investigation of SARS-CoV-2-specific antivirals is underway. Despite still being preclinical, these agents could be beneficial for the long-term control of COVID-19 and deserve more research focus. In this article, we update the current status of therapeutic candidates that have been examined for COVID-19 management, including the virus-targeting inhibitors and host-targeting agents, with their antiviral efficacy in vitro, in vivo, and in clinical studies. Finally, we highlight the current challenges and future prospect of developing potent therapeutic agents against COVID-19. |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/*therapy[MESH] |Humans[MESH] |Pandemics[MESH] |SARS-CoV-2/*physiology[MESH]Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prosp(epmc).pdf DeepDyve Pubget Overpricing